We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-13.03%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$696M
AUM Growth
-$298M
Cap. Flow
-$81.5M
Cap. Flow %
-11.71%
Top 10 Hldgs %
54.99%
Holding
76
New
17
Increased
7
Reduced
14
Closed
29

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$30.3M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$21.6M
3
AIMT
Aimmune Therapeutics
AIMT
+$18.5M
4
NGNE icon
Neurogene
NGNE
+$17.6M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$17.1M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$20.2M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$18.8M
3
DVAX
Dynavax Technologies
DVAX
+$17.9M
4
JUNO
Juno Therapeutics, Inc.
JUNO
+$14.9M
5
NVAX icon
Novavax
NVAX
+$14.2M

Sector Composition

Rank Sector Weight
1 Healthcare 85.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
76
DELISTED
Celgene Corp
CELG
– –
-8,700
Closed -$1.01M
1 2 3
4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, RA Capital Management held 76 positions worth $696M, down 30% from $994M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RA Capital Management withdrew a net $81.5M in Q3 2015, closing 29 positions and reducing 14 holdings. Its most notable exit was Medicines Co, an estimated $20.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 76% a quarter earlier.

Against the trend, RA Capital Management opened a new position in Zogenix, Inc. worth $22.7M.

  • RA Capital Management's largest Q3 2015 buy was Zogenix, Inc.: 1,679,500 shares worth $22.7M.
  • RA Capital Management added most to Achillion Pharmaceuticals in Q3 2015, an estimated $14.6M increase.
  • RA Capital Management's biggest Q3 2015 reduction was BioCryst Pharmaceuticals, cutting an estimated $18.8M.
  • RA Capital Management fully exited Medicines Co in Q3 2015, selling an estimated $20.2M.
  • RA Capital Management's ten largest holdings make up 55% of its $696M portfolio in Q3 2015.
  • RA Capital Management opened 17 new positions and closed 29 in Q3 2015.
  • RA Capital Management's portfolio value fell 30% quarter-over-quarter to $696M.

Based on RA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.